Hepatitis/MASH

Although hepatitis C virus medications are often costly to many patients, recent study results suggest that treating the disease can reduce absenteeism and increase productivity.

Concerns raised over treatment that fights fungal infections in lung transplant patients.

Improvements can be made to provide procedure-specific national benchmarks for postsurgical outcomes.

Pharmacists are ideally situated to help patients beat hepatitis C.

Entecavir treats chronic hepatitis B infection in adults with evidence of active viral replication.

Access to high cost curative antiviral HCV drugs remains a challenge for patients.

Findings may better predict organ rejection before transplantation.

An HCV infection may cause more than just liver damage.

Research may lead to a gel that instantly destroys viral particles.

Research could aid drug discovery.

Bill authorizes the VA to spend as much as $500 million for hepatitis C treatments.

Comorbidities lead to more complex treatment and higher costs.

Additional benefit from dasabuvir and combination of ombitasvir/paritaprevir/ritonavir found in pretreated genotype 1b hepatitis C patients without cirrhosis.

Hepatitis C drugs with high cure rates create new dilemma for people in need of transplantation.

A lymphotoxin-beta receptor inhibitor may stop the spread of the disease.

Single-tablet combination was previously granted two breakthrough therapy designations.

The FDA has granted priority review to Merck's chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.

Liver damage progresses at a more rapid pace in patients with HIV.

Sofosbuvir-based therapy offers the potential for high cure rates even in difficult-to-treat patient groups.

Treatment regimen was previously approved for 12 weeks in patients without cirrhosis or 24 weeks in those with cirrhosis.

A relationship between hepatitis C and cancer is reinforced by data from epidemiologic research.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.

Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).

Technivie with ribavirin is the first drug to demonstrate safety and efficacy in genotype 4 infections without interferon.

Company alleges insurers are taking advantage of program to shift cost of Sovaldi.